Development

Genentech's Tecentriq gets FDA nod as adjuvant for muscle-invasive bladder cancer treatment

Genentech has secured an atezolizumab bladder cancer FDA approval for the adjuvant treatment of muscle-invasive bladder cancer, with the US FDA clearing...

Edited by Robert McTiernan··3 min read

Genentech has secured new indication approval from the US FDA for atezolizumab (Tecentriq) and the subcutaneous formulation atezolizumab hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant treatment in muscle-invasive bladder cancer (MIBC). Specifically, the approval covers Tecentriq's use in adults with MIBC after cystectomy who have circulating tumor DNA molecular residual disease detected by an FDA-authorized test — a biomarker-selected indication that marks a first in this post-surgical setting.

Efficacy data supporting the approval came from IMvigor011 (NCT04660344), a multi-center, randomized, double-blind, placebo-controlled Phase III trial that enrolled 250 patients with MIBC following radical cystectomy with lymph node dissection. Enrollment required detection of ctDNA MRD through serial blood-based evaluation during the 12 months post-cystectomy, beginning at least six weeks after surgery. Patients were randomized 2:1 to receive atezolizumab 1680 mg intravenously every four weeks or placebo, with treatment continuing for up to 12 cycles or one year unless disease recurrence or unacceptable toxicity occurred.

The trial's use of ctDNA MRD as an enrollment criterion reflects a patient-stratification approach that has gained traction across oncology over the past several years. Rather than treating all post-cystectomy patients, IMvigor011 targeted only those with detectable residual disease at the molecular level — a population at elevated risk of recurrence and therefore more likely to derive benefit from adjuvant intervention.

Key efficacy results

The primary endpoint was investigator-assessed disease-free survival. Atezolizumab produced a median DFS of 9.9 months (95% CI: 7.2–12.7) compared with 4.8 months (95% CI: 4.1–8.3) for placebo, a difference that reached statistical significance with a hazard ratio of 0.64 (95% CI: 0.47–0.87; p=0.0047). The overall survival data also favored atezolizumab, with a median OS of 32.8 months (95% CI: 27.7–not estimable) versus 21.1 months (95% CI: 14.7–not estimable) in the placebo arm, yielding an HR of 0.59 (95% CI: 0.39–0.90; p=0.0131).

The OS result is notable in a 250-patient trial, though the confidence intervals are wide and the upper bound for placebo remains unevaluable, reflecting the relatively limited follow-up and sample size. Both endpoints nonetheless met pre-specified statistical thresholds, providing the evidentiary basis for the priority review designation the application received.

The prescribing information carries warnings for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicity — a safety profile consistent with the established class characteristics of PD-L1 checkpoint inhibitors.

The AllSci BriefSystematic R&D and deal news. Daily.

Competitive positioning in the adjuvant MIBC landscape

The approval positions atezolizumab as the only therapy with a label specifically restricted to ctDNA MRD-positive MIBC post-cystectomy. Two other checkpoint inhibitors carry adjuvant or perioperative MIBC approvals in broader, unselected populations. AstraZeneca's Imfinzi (durvalumab) received FDA approval in March 2025 for perioperative use — neoadjuvant in combination with chemotherapy followed by adjuvant monotherapy — without a ctDNA MRD requirement. Bristol Myers Squibb's Opdivo (nivolumab) has carried an adjuvant label for high-risk urothelial carcinoma post-radical resection since 2021, also without biomarker-based selection.

Treating an unselected post-cystectomy population exposes ctDNA-negative patients — who may have lower recurrence risk — to immunotherapy toxicity without clear evidence of benefit. The bladder cancer molecular residual disease treatment framework embedded in the atezolizumab approval attempts to resolve that tension by restricting therapy to those with confirmed residual disease. Cross-trial comparisons are limited by differences in patient populations, endpoints, follow-up duration, and trial design, making direct efficacy comparisons between atezolizumab, durvalumab, and nivolumab in the adjuvant setting unreliable.

The broader competitive context involves Merck's Keytruda (pembrolizumab) and nivolumab, which dominate checkpoint inhibitor use across multiple oncology indications. Pembrolizumab, in combination with enfortumab vedotin (Padcev), received FDA approval in November 2025 for neoadjuvant MIBC treatment followed by adjuvant treatment after cystectomy for cisplatin-ineligible adults with MIBC, meaning it partially overlaps with the perioperative/post-cystectomy treatment landscape but differs from atezolizumab’s ctDNA MRD-selected adjuvant-only indication.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article